Juno-founders get opportunity to buy Danish-founded biotech company

A new company, founded by the team behind Juno Therapeutics, has granted a investment to Oscine Therapeutics that develops cell therapies against neurological disorders. Moreover, Oscine has given the investor an opportunity to buy the company when the phase I trials are finished.

Photo: /Ritzau Scanpix/Asger Ladefoged

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles